The CMAB management team has extensive experience gained from international biopharmaceutical companies and has collectively delivered more than 100 CMO projects, resulting in at least 40 IND applications for biological drugs.


CMAB was founded to provide international-standard development and manufacturing services for biologic products.  Our initial focus is on pre-clinical and early-stage clinical (Phase I/II) products for customers in China and across the globe.

CMAB have the vision to be the leading CDMO in China and plan rapid expansion to provide a global footprint and compelling commercial production capability.


Qibin Liang, President CMAB BioPharm, China
A veteran of the international biotech industry, Liang Qibin started his career in biologics manufacturing after completing a Bachelor of Science (Chemical Engineering) from East China University of Technology and going on to earn a Master of Science (Chemical Engineering) degree from University of Idaho.


In his early roles he worked for leading US-based biopharmaceutical companies where he managed upstream and downstream manufacturing departments to produce a range of late-stage and commercial biologic products including Bayer’s commercial Factor VIII product manufactured by perfusion process.


Since 2011 Liang Qibin has been working in China where he has been instrumental in setting up three biologics development and manufacturing companies.  Immediately before joining CMAB, Liang QiBin was the President of MabPlex International, China.
Michael Frizberg, President CMAB Hong Kong
With more than two decades of international commercial experience, Michael Frizberg is responsible for CMAB’s global strategy and business development.
Michael’s talent for business started in Hong Kong and soon after his responsibilities expanded to cover global market research for the then Sanofi & Aventis group before moving to Lonza.  At Lonza Michael was responsible for key initiatives related to the company’s biosimilars and China joint venture strategy for Fosun.  His responsibilities grew to be head of sales & KAM, pharma and biotech achieving USD1.6bn global sales.  Immediately before joining CMAB, Michael was General Manager, Luye Supply AG.


Michael holds a Bachelor degree in Arts and a Master degree in Business Administration from Universität Augsburg.
Liming Shi, Senior Director Quality Control
Liming Shi has 21 years’ biologics experience in biopharmaceutical industry. He has previously worked at Genentech, Amgen, Amylin, Eli Lilly and Pfizer. Liming specializes in bioassay development, qualification and validation; tech transfer, CRO management, quantitative assay performance management with trending analysis and deviation investigation; and all kinds of analytical methods in biologics development. His unique background combines proven experience in both project and team management; thorough expertise in biostatistics, DOE, QbD; all kinds of analytical technology. His deep understanding of cGMP/cGLP; FDA/NMPA/EMA, ICH regulatory guidance; USP/ChP/EP chapters; his strong CMC and analytical lead experience provided critical support in numerous IND and BLA submissions. Liming has instructed 12 seminars/training workshops and chaired many conference sessions in the past six years in addition to being a frequent conference speaker for almost twenty years. Liming now is a member of Scientific Advisory Committee for BioProcess International. Liming holds two Master degrees – one in Biophysics and the other in Biochemistry – as well as ADMET certification.
Dr. Simon Kwong, Vice President PD & AD
Passionate about developing new products, Simon has been at the forefront of the biologics industry in China for more than two decades.
At the Hong Kong Institute of Biotechnology he designed, built and managed the first internationally-approved GMP pilot fermentation facilities in China to produce a novel anti-malaria vaccine with NIH for USIND and complete multiple CMO projects for local and MNCs. Next he Cofounded Sinomab Bioscience Limited, and as VP Operations, he built two more facilities and led teams to achieve IND filings of several therapeutic Mabs before accepting the position of General Manager at Lonn Ryonn Pharma where he developed multiple products for international clinical programs.
Before joining CMAB, Simon was VP, PD and CMO plus Acting GM for JHL Biotech Wuhan where he managed the site PD, CMC, and manufacturing activities of internal and CMO projects during the start-up the 4 x 2000L KuBio plant.
Simon holds a Bachelor degree in Chemical Engineering and Doctorate of Philosophy in Chemical and Biochemical Engineering from the University of Maryland.
Dr. Nick Kotlarski, Vice President Facilities
After finishing his first clinical manufacturing facility in 1995, Nick subsequently held Manufacturing head responsibilities for three other clinical biologic manufacturing facilities in Australia.  In 2007 he relocated to Singapore as Principal Consultant, and later General Manager, of an engineering firm active throughout ASEAN countries and China serving pharma and biotech clients.
Prior to joining CMAB , Nick was VP of Facilities and Engineering for JHL Biotech where he managed a capital expenditure program of US$80m over three years that delivered two GMP pilot plants and a commercial facility with modular KUBio® building for manufacture of cell culture products.
Nick holds a Bachelor degree in Chemical Engineering and a Doctorate of Philosophy from the University of Adelaide.  He is a Charted Engineer, Member of the Institution of Chemical Engineers, and Member of ISPE.
Peter Wang, Vice President Manufacturing
Peter brings extensive hands-on manufacturing experience coupled with management and business experience to CMAB where he is responsible for the manufacturing operations of drug substance and drug product, as well as Warehouse & Logistics.
Peter initially worked in purification processes development and manufacturing of and filling for biologics at KOSAN Biosciences and Genentech.  He took a position with Amgen as part of the commercial drug product team and managed commercial CMOs in the US and Germany before joining JHL Biotech to build and lead their purification operations as well as Business Development.
Immediately prior to joining CMAB, Peter was Senior Director at WuXi Biologics where he led installation, qualification, and startup of the cell culture and purification operations of their 30,000L commercial manufacturing facility.
Peter holds a Bachelor degree in Chemical Engineering from University of British Columbia and Master of Business Administration degree from University of Southern California.